## CLX: Clorox Company (The) - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -4.4% below STRENGTH zone (3.0-6.0%); PEG 3.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.48)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Clorox Co. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251208T163000 | Neutral | Relevance: 99%
- Shares of Clorox Co. (CLX) fell by 3.78% to $100.93 on Monday, experiencing its sixth consecutive day of losses. This performance occurred during a dismal trading session where the S&P 500 Index (SPX) dropped 0.35% and the Dow Jones Industrial Average (DJIA) fell 0.45%.

**2. The Clorox Company $CLX Position Increased by Federated Hermes Inc.**
- Source: MarketBeat | 20251209T100813 | Neutral | Relevance: 98%
-  Federated Hermes Inc. has significantly increased its stake in The Clorox Company (NYSE:CLX) by 35.6% during the second quarter, now owning 460,646 shares worth $55.31 million. Other institutional investors also adjusted their positions, and a company director recently purchased additional shares. Analyst ratings for Clorox are mixed, with an average rating of "Reduce" and an average price target of $125.69.

**3. Amundi Increases Stock Position in The Clorox Company $CLX**
- Source: MarketBeat | 20251208T081429 | Neutral | Relevance: 98%
-  Amundi recently increased its stake in The Clorox Company (NYSE:CLX) by 1.1% in Q2, acquiring 10,108 additional shares to hold a total of 940,399 shares valued at $117.23 million. The company reported Q3 EPS of $0.85, beating estimates, but revenue decreased by 18.9% year-over-year. Clorox also announced a quarterly dividend of $1.24 and saw insider buying from a director.

**4. Clorox (CLX): Assessing Valuation After a 35% Share Price Slide and Modest Earnings Growth**
- Source: Simply Wall Street | 20251208T000911 | Somewhat-Bullish | Relevance: 98%
-  Clorox (CLX) has experienced a significant 35% share price decline over the past year despite posting modest revenue and earnings growth, leading to questions about its current valuation. Analysts see potential upside, with a narrative suggesting the stock is 15.8% undervalued based on assumptions about an ERP system implementation improving long-term efficiencies. However, this upside depends on Clorox navigating intense price competition and stabilizing demand.

**5. Clorox: Headwinds Linger, But Its Near 5% Yield Makes It Hard To Ignore (NYSE:CLX)**
- Source: Seeking Alpha | 20251209T083000 | Somewhat-Bullish | Relevance: 97%
- Clorox (CLX) is facing near-term challenges with a weak FY26 outlook predicting declines in sales and EPS, but it presents a compelling long-term investment opportunity due to its 4.6% dividend yield and current depressed valuation. Management anticipates improvements in the latter half of FY26 through digital transformation and product innovation, though benefits may take 1-2 years to fully materialize. With a forward P/E of 17.3x and a FY28 price target of $153.34, patient investors could see double-digit upside.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 21 ($20.47M) |
| Sells | 4 ($1.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Long-term trend broken: trading 20.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.44 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Insider buying signal ($20.5M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.4B |
| Beta | 0.57 |
| 52W Range | $98.20 - $169.61 |
| Short Interest | 6.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.44 |
| Forward P/E | 15.0 |
| Current P/E | 16.9 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.8% to -4.4% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.80x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.38% (CS: 11) | Weak |
| RSI_14 | 35.0 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.911x | Below |
| vs SMA200 | 0.799x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.42
- **Stop Loss:** $96.48 (4.9% risk)
- **Target:** $106.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 101
- **Position Value:** $10,243.42
- **Portfolio %:** 10.24%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*